Inflammatory bowel disease (IBD) pathogenesis is associated with gut mucosal
inflammation, epithelial damage, and dysbiosis leading to a dysregulated gut mucosal …

Recent research on bilirubin, a historically well-known waste product of heme catabolism,
suggests an entirely new function as a metabolic hormone that drives gene transcription by …

The incidence of inflammatory bowel disease (IBD) is rapidly rising throughout the world.
Although tremendous efforts have been made, limited therapeutics are available for IBD …

Despite significant advances in immune checkpoint blockade (ICB), immunosuppression
mediated by tumor-associated myeloid cells (TAMCs) poses a major barrier to cancer …

The initiation and development of major inflammatory diseases, ie, cancer, vascular
inflammation, and some autoimmune diseases are closely linked to the immune system …

Therapies modulating the immune system offer the prospect of treating a wide range of
conditions including infectious diseases, cancer and autoimmunity. Biomaterials can …

The microbiome is emerging as a key player and driver of cancer. Traditional modalities to
manipulate the microbiome (for example, antibiotics, probiotics and microbiota transplants) …

Smart delivery systems with stimuli-responsive capability are able to improve the
bioaccessibility through increasing the solubility, physicochemical stability and …

The delivery of probiotics to the microbiota is a promising method to prevent and treat
diseases. However, oral probiotics will suffer from gastrointestinal insults, especially the …

Helicobacter pylori (H. pylori) infection is the leading cause of chronic gastritis, peptic ulcer,
and gastric cancer. Antibiotics, as traditional method for eliminating H. pylori, have no …